This Week’s CGT News: Promising Data for In Vivo CAR T
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
Clinical Scorecard: This Week’s CGT News: Promising Data for In Vivo CAR T
At a Glance
Category Detail
Condition B-cell malignancies, multiple myeloma, end-stage kidney disease Key Mechanisms In vivo CAR T cell therapy targeting CD19/CD20 and BCMA Target Population Patients with relapsed or refractory cancers and end-stage kidney disease Care Setting Clinical trials and transplant centers
Key Highlights
Phase 1 data shows complete response in 5 out of 6 patients treated with LB2501 for lymphoma. All 18 patients with relapsed or refractory multiple myeloma showed no signs of disease after treatment with Kelonia's CAR T therapy. Dual CAR T therapy enabled two patients with end-stage kidney disease to receive kidney transplants. Guideline-Based Recommendations
Diagnosis
Assessment of lymphoma and multiple myeloma through clinical evaluation and imaging. Management
Utilization of in vivo CAR T therapies for eligible patients. Monitoring & Follow-up
Monitoring for cytokine release syndrome and other treatment-related adverse effects. Risks
Potential for cytokine release syndrome in CAR T therapy recipients. Patient & Prescribing Data
Patients with B-cell malignancies and multiple myeloma.
Higher doses of CAR T therapy show promising efficacy with manageable safety profiles.
Clinical Best Practices
Consider dual CAR T therapy for highly sensitized kidney transplant candidates. Monitor patients closely for cytokine release syndrome post-CAR T therapy. Related Resources & Content
